CBPO  China Biologic Products Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

3.03B

Vuru Grade

72.45/100

Current Price

$111.52
+0.31 (+0.28%)

Growth Price

$38.84
Overvalued by 65.17%

Stability Price

$21.64
Overvalued by 80.60%

Company Metrics

  • P/E 30.58
  • P/S 9.1
  • P/B 6.34
  • EPS 3.65
  • Cash ROIC 27.80%
  • Cash Ratio 2.02
  • Dividend 0 / 0%
  • Avg. Vol. 169,815.00
  • Shares 27.17M
  • Market Cap. 3.03B

Company Description

China Biologic Products, Inc., a biopharmaceutical company, engages in the research, development, production, and manufacture of plasma-based pharmaceutical products in the People's Republic of China. It offers Human Albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

China Biologic to Build New Collection Station and New Branch Collection ...
PR Newswire (press release) - Jan 6, 2017
BEIJING, Jan. 6, 2017 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its majority-owned subsidiary ...
China Biologic to Attend the 35th Annual J.P. Morgan Healthcare Conference
PR Newswire (press release) - Jan 4, 2017
China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company will participate in the 35th Annual J.P.
CHINA BIOLOGIC PRODUCTS, INC. (NASDAQ:CBPO) Files An 8-K Regulation FD Disclosure - Market Exclusive
China Biologic Products, Inc. (CBPO) Stock Rating Lowered by Zacks Investment ... - Sports Perspectives
China Biologic Announces Secondary Offering of Common Stock
PR Newswire (press release) - Mar 1, 2016
BEIJING, March 1, 2016 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading plasma-based biopharmaceutical company in China, today announced that Warburg Pincus Private Equity X, L.P.
Warburg Pincus to offload 3.5 mln China Biologic shares in secondary offering - Thomson Reuters' peHUB (press release)
China Biologic Acquires Full Ownership of Guizhou Taibang
PR Newswire (press release) - Oct 26, 2016
BEIJING, Oct. 26, 2016 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that Guizhou Taibang Biological ...
China Biologic Opens Plasma Collection Station in Hebei Province
PR Newswire (press release) - Jun 20, 2016
BEIJING, June 20, 2016 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company's majority-owned ...
China Biologic Products, Inc. (NASDAQ:CBPO) Average Rating At 3.5
Markets Daily - Jan 21, 2017
If you are trying to comprehend what methodology Alpha One plans to achieve stock sentiment, then it is dynamic to understand about algorithm based analytics.
Option Market: China Biologic Products Inc Risk Hits A Lowered Level
CML News - Jan 19, 2017
We're going to look at a proprietary risk rating for the next 30-days built by Capital Market Laboratories (CMLviz) based on a large number of interactions of data points, many of which come directly from the option market for China Biologic Products ...
Shares of China Biologic Products, Inc. (NASDAQ:CBPO) Sees Large Inflow of Net ...
TheFounders Daily - Jan 22, 2017
China Biologic Products, Inc. (NASDAQ:CBPO) traded with a cut of -0.1 points or -0.09% at $107.31 per share. As per the last available information, the stock aggregated $5.65 million in upticks and $2.02 million in downticks, keeping the net money flow ...
China Biologic Products, Inc. (NASDAQ:CBPO) Receives An Update From Brokers - The De Soto Edge
Next Weeks Broker Price Targets For China Biologic Products, Inc. (NASDAQ:CBPO) - Fiscal Standard
China Biologic Products: An Alternative To The U.S Sector
Seeking Alpha - May 17, 2016
China Biologic Products Inc. is a mid cap biotech focused on plasma based technology. The firm manufactures twenty products for use in emergency rooms and in the treatment of immuno-deficiency related illnesses.
China Biologic Receives CFDA Clinical Trial Approval for Human Coagulation ...
PR Newswire (press release) - Sep 19, 2016
BEIJING, Sept. 19, 2016 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that Shandong Taibang Biological ...